Chimerix (NASDAQ:CMRX) Hits New 1-Year High – What’s Next?

Chimerix, Inc. (NASDAQ:CMRX)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $8.55 and last traded at $8.55, with a volume of 805519 shares. The stock had previously closed at $8.54.

Analysts Set New Price Targets

CMRX has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com initiated coverage on shares of Chimerix in a research report on Tuesday, April 8th. They issued a “hold” rating for the company. HC Wainwright restated a “neutral” rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Performance

The stock has a market cap of $801.56 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. The stock’s 50-day simple moving average is $7.04 and its two-hundred day simple moving average is $3.80.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. As a group, research analysts predict that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Insider Activity at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Bender Robert & Associates acquired a new stake in shares of Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new position in Chimerix during the 4th quarter worth about $59,000. Jane Street Group LLC acquired a new stake in shares of Chimerix during the fourth quarter worth $62,000. Diadema Partners LP bought a new position in shares of Chimerix in the 4th quarter worth about $101,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Chimerix in the 4th quarter valued at $130,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.